Jasper Therapeutics/$JSPR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.

Ticker

$JSPR
Sector
Health
Primary listing
NASDAQ

Employees

22
Headquarters
Redwood City, United States
Website
jaspertx.com

JSPR Metrics

BasicAdvanced
$25m
-
-$2.47
-
-

What the Analysts think about JSPR

Analyst ratings (Buy, Hold, Sell) for Jasper Therapeutics stock.

JSPR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37bn
-39.75%
Net income
$45bn
107.52%
Profit margin
37.65%
6.78%

JSPR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $JSPR

Sign up or log in to buy
Capital at risk
Market closedLow-cap

Upcoming events

No upcoming events
FAQs